Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alisma orientalis, also known as Alisma plantago-aquatica subsp. orientale (Sam.) Sam. or "zexie," is a traditional Chinese medicinal plant. It is a key ingredient in the Alisma orientalis beverage (AOB), a traditional Chinese medicine formulation traditionally used for treating metabolic syndrome and atherosclerosis. Research indicates that Alisma orientalis itself possesses antisteatosis effects, including modulation of lipogenesis, antilipoapoptosis, and anti-inflammation, and contributes to lipid-lowering effects. When formulated as AOB, it has been shown to exert antiatherosclerotic effects by regulating gut microbiota, reducing trimethylamine N-oxide (TMAO) levels, and decreasing hepatic flavin-containing monooxygenase 3 (FMO3) expression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alisma orientalis.